Oramed Pharmaceuticals Stock Forecast

Stock Price Forecast

There is currently no analyst price target forecast available for Oramed Pharmaceuticals.

Analyst Consensus: n/a

Target	Low	Average	Median	High
Price	n/a	n/a	n/a	n/a
Change	n/a	n/a	n/a	n/a

Analyst Ratings

There are currently no analyst ratings available for Oramed Pharmaceuticals.

Recommendation Trends

Rating	Apr '24	May '24	Jun '24	Jul '24	Aug '24
Strong Buy	0	0	0	0	0
Buy	0	0	0	0	0
Hold	2	1	1	1	1
Sell	0	0	0	0	0
Strong Sell	0	0	0	0	0
Total	2	1	1	1	1

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Raghuram Selvaraju HC Wainwright & Co.	HC Wainwright & Co.	Hold Reiterates n/a	Hold	Reiterates	n/a	n/a	Sep 9, 2024
Raghuram Selvaraju HC Wainwright & Co.	HC Wainwright & Co.	Hold Reiterates n/a	Hold	Reiterates	n/a	n/a	May 20, 2024
Edward Nash Canaccord Genuity	Canaccord Genuity	Hold Maintains $3 → $2	Hold	Maintains	$3 → $2	-25.65%	May 17, 2023
Raghuram Selvaraju HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy → Hold Downgrades n/a	Strong Buy → Hold	Downgrades	n/a	n/a	Jan 17, 2023
Edward Nash Canaccord Genuity	Canaccord Genuity	Strong Buy → Hold Downgrades n/a	Strong Buy → Hold	Downgrades	n/a	n/a	Jan 12, 2023

More Analyst Ratings

Financial Forecast

Revenue This Year

2.04M

Revenue Next Year

n/a

from 2.04M

EPS This Year

1.32

from -0.48

EPS Next Year

n/a

from 1.32

Fiscal Year	FY 2021	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025
Period Ending	Aug 31, 2021	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025
Revenue	2.70M	2.71M	2.70M	1.34M	-	2.04M
Revenue Growth	-0.33%	0.33%	-0.33%	-50.43%	-	-
EPS	-0.78	-0.94	-0.94	0.14	-0.48	1.32
EPS Growth	-	-	-	-	-	-
Forward PE	-	-	-	-	-	2.04
No. Analysts	-	-	-	-	-	3

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025
High	2.1M
Avg	2.0M
Low	2.0M

Revenue Growth

Revenue Growth	2025
High	-
Avg	-
Low	-

EPS Forecast

EPS	2025
High	1.35
Avg	1.32
Low	1.26

EPS Growth

EPS Growth	2025
High	-
Avg	-
Low	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.